MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas. The company processes the human amniotic membrane utilizing its proprietary PURION Process to produce an implant. It also supplies amniotic tissue comprising approximately 500,000 allografts for applications in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. In addition, it provides OrthoFlo, an amniotic fluid derived allograft for homologous use. Further, the company’s proprietary platforms include Physio, a unique bone grafting material for maximizing bone forming potential and a demineralized bone matrix; and AlloBurn, a skin product for burns. Additionally, it offers CollaFix, a collagen fiber technology developed with the company’s patented cross-linking polymers, designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. The CollaFix is the biological, biodegradable, and biomimetic technology that matches human tendon in strength and stiffness. The company primarily provides regenerative medicine specialties in wound care, and surgical, sports medicine, and orthopedics with spinal procedures. It sells its products through direct sales force, and independent stocking distributors and representatives in the United States, as well as independent distributors internationally. The company is headquartered in Marietta, Georgia.